Ofev (nintedanib) is not a chemotherapy drug. It belongs to a class of medications called kinase inhibitors, and it is prescribed to slow the progression of lung scarring diseases, not to kill cancer cells. The confusion is understandable, though, because the same active ingredient has been studied in cancer treatment under a different brand name, and some of its biological targets overlap with those of certain cancer therapies.
What Ofev Actually Is
Ofev is classified by the FDA as a kinase inhibitor. It works by blocking specific proteins called receptor tyrosine kinases, which act as signals that tell cells to grow, multiply, and form new blood vessels. In the lungs, these signals can drive the uncontrolled scarring process that makes diseases like idiopathic pulmonary fibrosis (IPF) progressively worse.
By blocking these growth signals, Ofev reduces the ability of fibroblasts (the cells responsible for producing scar tissue) to proliferate, migrate, and survive. This slows the rate at which healthy lung tissue is replaced by stiff, non-functional scar tissue. It does not reverse existing scarring, but it can meaningfully slow the decline in lung function over time.
Why People Confuse It With Chemotherapy
The confusion has a real basis. Nintedanib, the active ingredient in Ofev, has been studied as a cancer treatment under the brand name Vargatef. In that context, it has been tested in combination with traditional chemotherapy drugs for non-small cell lung cancer. Clinical trials have evaluated nintedanib at higher doses (400 mg per day) alongside intravenous chemotherapy for patients whose cancer did not respond to first-line treatment.
The mechanism also sounds cancer-related. Ofev blocks growth factor receptors that play roles in tumor blood vessel formation, the same pathway that some targeted cancer therapies aim to disrupt. But in its FDA-approved form as Ofev, the drug is not indicated for cancer. It is approved specifically for lung fibrosis conditions.
What Ofev Is Prescribed For
Ofev is approved to treat IPF, a chronic disease where the lungs become increasingly scarred for unknown reasons. It is also approved for other forms of progressive pulmonary fibrosis and for a type of lung scarring associated with a connective tissue disease called systemic sclerosis. International clinical practice guidelines from the American Thoracic Society and other major respiratory organizations include nintedanib as a recommended treatment for these conditions.
How Taking Ofev Differs From Chemotherapy
The day-to-day experience of taking Ofev looks nothing like traditional chemotherapy. It is an oral capsule taken twice daily with food, about 12 hours apart. There are no infusions, no treatment cycles, and no visits to an infusion center. You take it at home as part of your daily routine, swallowing the capsule whole with liquid. The standard dose is 150 mg twice daily, with a lower dose available for people with mild liver impairment.
The side effect profile also differs significantly from chemotherapy. The most common side effects of Ofev are gastrointestinal: diarrhea, nausea, stomach pain, and decreased appetite. Some people experience headaches, fatigue, dizziness, weight loss, or back pain. Notably, Ofev does not cause hair loss, one of the most recognized side effects of traditional chemotherapy. It also does not suppress the immune system the way most chemotherapy drugs do.
Chemotherapy works by killing rapidly dividing cells throughout the body, which is why it causes widespread side effects like hair loss, immune suppression, and mouth sores. Ofev works through a more targeted mechanism, blocking specific growth factor signals rather than broadly attacking dividing cells. This is a fundamental difference in how the two types of drugs operate.
Managing Side Effects
Diarrhea is the most frequently reported issue with Ofev and can sometimes be significant enough to require a dose reduction. If you miss a dose, the guidance is to simply take the next one at your regularly scheduled time rather than doubling up. The maximum daily dose is 300 mg (two 150 mg capsules), and exceeding that is not recommended.
Liver function is monitored during treatment because kinase inhibitors can affect liver enzymes. Your doctor will typically check bloodwork periodically to make sure your liver is handling the medication well. This is routine monitoring, not the intensive lab work and blood count tracking that comes with chemotherapy regimens.